New Delhi, Oct. 31 -- Indian drug regulators have directed Sun Pharmaceutical Industries, the country's largest pharmaceutical company, to stop manufacturing, selling and distributing ophthalmic products produced at its Assam facility after identifying significant deficiencies in its quality management system.

According to documents reviewed by Reuters, the Central Drugs Standard Control Organisation (CDSCO) and the office of the Drugs Controller, Assam, issued the order on August 20 following a joint inspection by central and state drug regulators.

The action came after Sun Pharma voluntarily recalled around 11 eye-care brands, along with all ophthalmic products manufactured at the facility, in July. The regulators have also sought add...